PT - JOURNAL ARTICLE AU - Ali Rostami AU - Mahdi Sepidarkish AU - Mariska Leeflang AU - Seyed Mohammad Riahi AU - Malihe Nourollahpour Shiadeh AU - Sahar Esfandyari AU - Ali H Mokdad AU - Peter J. Hotez AU - Robin B. Gasser TI - First “snap-shot” meta-analysis to estimate the prevalence of serum antibodies to SARS-CoV-2 in humans AID - 10.1101/2020.08.31.20185017 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.31.20185017 4099 - http://medrxiv.org/content/early/2020/09/02/2020.08.31.20185017.short 4100 - http://medrxiv.org/content/early/2020/09/02/2020.08.31.20185017.full AB - Background COVID-19 is arguably the number-one public health concern worldwide, and efforts are now escalating to control its spread.Objective In this study, we undertake a meta-analysis to estimate the global and regional anti-SARS-CoV-2 seroprevalence rates in humans and assess whether seroprevalence associates with geographical, climatic and socio-demographic factors.Data sources We systematically reviewed PubMed, Scopus, Embase, medRxiv and bioRxiv for peer-reviewed articles or preprints (up to 14 August 2020).Study eligibility criteria Population-based studies describing prevalence of anti-SARS-CoV-2 serum antibodies in general people.Participants general people who were tested for prevalence of anti-SARS-CoV-2 serum antibodies.Interventions There were no interventions.Methods We used random-effects model to estimate pooled seroprevalence, and then extrapolated these findings to the global population (for 2020). Sub-group and meta-regression analyses explored potential sources of heterogeneity in the data and relationships between seroprevalence and socio-demographic, geographical and climatic factors.Results In total, 47 serological studies involving 399,265 people from 23 countries met the inclusion criteria. The pooled seroprevalence of SARS-CoV-2 in general people was estimated at 3.38% (95% CI, 3.05%–3.72%; 15,879/399,265). On a regional basis, we determined seroprevalence estimates of 5.27% (3.97–6.57%) in Northern Europe; 4.41% (2.20–6.61%) in Southern Europe; 4.41% (3.03– 5.79%) in North America; 3.17% (1.96–4.38%) in Western Europe; 2.02% (1.56–2.49%) in the Eastern Asia; and 1.45% (0.95–1.94%) in South America. Extrapolating to the 2020 world population, we estimated that 263,565,606 individuals had been exposed or infected with SARS-CoV-2 at the first wave of the pandemic. A significantly higher seroprevalence was related to higher income levels and human development indices, higher geographical latitudes and lower mean environmental temperatures.Interpretation This study reinforces that SARS-CoV-2 infection is a very rapidly-spreading communicable disease and calls for routine surveys to constantly monitor temporal changes in seroprevalence around the globe.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere is no funding source for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:this study was approved by ethical committee of Babol University of Medical ScienceAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data related with this study are available in the manuscript and supplementary files.